The DPP-4 inhibitor vildagliptin impacts the gut microbiota and prevents disruption of intestinal homeostasis induced by a Western diet in mice

Diabetologia

Volumn 61, Issue 8, 2018, Pages 1838-1848

  Olivares, Marta ^a   Neyrinck, Audrey M ^a   Pötgens, Sarah A ^a   Beaumont, Martin ^a   Salazar, Nuria ^b   Cani, Patrice D ^a   Bindels, Laure B ^a   Delzenne, Nathalie M ^a  

^a UNIVERSITÉ CATHOLIQUE DE LOUVAIN   (Belgium)

^b DEPARTMENT OF MICROBIOLOGY AND BIOCHEMISTRY OF DAIRY PRODUCTS   (Spain)

Author keywords

Antimicrobial peptides; DPP 4 activity; Gut microbiota; Gut liver axis; Vildagliptin; Western diet

Indexed keywords

CD163 ANTIGEN; CLAUDIN 2; GLUCAGON LIKE PEPTIDE 1; GLUCOSE; GLYCOPROTEIN P 15095; INSULIN; POLYPEPTIDE ANTIBIOTIC AGENT; RNA 16S; TOLL LIKE RECEPTOR 2; TOLL LIKE RECEPTOR 4; VILDAGLIPTIN; ANTIDIABETIC AGENT; CYTOKINE; DIPEPTIDYL PEPTIDASE IV INHIBITOR; VOLATILE FATTY ACID;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BACTERIAL GROWTH; BODY WEIGHT; CONTROLLED STUDY; FECES; FOOD INTAKE; GENE EXPRESSION; GLUCOSE BLOOD LEVEL; GLUCOSE HOMEOSTASIS; HEPATIC PORTAL VEIN; IN VITRO STUDY; INTESTINE FLORA; INTESTINE FUNCTION; LIVER SLICE; MALE; MOUSE; NONHUMAN; OBESITY; PRIORITY JOURNAL; SCANNING ELECTRON MICROSCOPY; WESTERN DIET; ANIMAL; C57BL MOUSE; DRUG EFFECT; ECOSYSTEM; GENE EXPRESSION PROFILING; HOMEOSTASIS; INFLAMMATION; INTESTINE; LIVER; METABOLISM; MICROBIOLOGY;

ANIMALS; CYTOKINES; DIET, WESTERN; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; ECOSYSTEM; FATTY ACIDS, VOLATILE; GASTROINTESTINAL MICROBIOME; GENE EXPRESSION PROFILING; HOMEOSTASIS; HYPOGLYCEMIC AGENTS; INFLAMMATION; INTESTINES; LIVER; MALE; MICE; MICE, INBRED C57BL; OBESITY; VILDAGLIPTIN;

EID: 85047363662     PISSN: 0012186X     EISSN: 14320428     Source Type: Journal    
DOI: 10.1007/s00125-018-4647-6     Document Type: Article

References (50)

1. Seino Y, Fukushima M, Yabe D (2010) GIP and GLP-1, the two incretin hormones: similarities and differences. J Diabetes Investig 1:8–23
2. Mulvihill EE, Drucker DJ (2014) Pharmacology, physiology, and mechanisms of action of dipeptidyl peptidase-4 inhibitors. Endocr Rev 35:992–1019
3. Lee SA, Kim YR, Yang EJ et al (2013) CD26/DPP4 levels in peripheral blood and T cells in patients with type 2 diabetes mellitus. J Clin Endocrinol Metab 98:2553–2561
4. Stengel A, Goebel-Stengel M, Teuffel P et al (2014) Obese patients have higher circulating protein levels of dipeptidyl peptidase IV. Peptides 61:75–82
5. Sell H, Bluher M, Kloting N et al (2013) Adipose dipeptidyl peptidase-4 and obesity: correlation with insulin resistance and depot-specific release from adipose tissue in vivo and in vitro. Diabetes Care 36:4083–4090
6. Kushwaha RN, Haq W, Katti SB (2014) Sixteen-years of clinically relevant dipeptidyl peptidase-IV (DPP-IV) inhibitors for treatment of type-2 diabetes: a perspective. Curr Med Chem 21:4013–4045
7. Waget A, Cabou C, Masseboeuf M et al (2011) Physiological and pharmacological mechanisms through which the DPP-4 inhibitor sitagliptin regulates glycemia in mice. Endocrinology 152:3018–3029
8. Mulvihill EE, Varin EM, Gladanac B et al (2017) Cellular sites and mechanisms linking reduction of dipeptidyl peptidase-4 activity to control of incretin hormone action and glucose homeostasis. Cell Metab 25:152–165
9. Mortier A, Gouwy M, Van Damme J, Proost P, Struyf S (2016) CD26/dipeptidylpeptidase IV-chemokine interactions: double-edged regulation of inflammation and tumor biology. J Leukoc Biol 99:955–969
10. Yazbeck R, Howarth GS, Abbott CA (2009) Dipeptidyl peptidase inhibitors, an emerging drug class for inflammatory disease? Trends Pharmacol Sci 30:600–607
11. Hartmann B, Thulesen J, Kissow H et al (2000) Dipeptidyl peptidase IV inhibition enhances the intestinotrophic effect of glucagon-like peptide-2 in rats and mice. Endocrinology 141:4013–4020
12. Wronkowitz N, Gorgens SW, Romacho T et al (2014) Soluble DPP4 induces inflammation and proliferation of human smooth muscle cells via protease-activated receptor 2. Biochim Biophys Acta 1842:1613–1621
13. Lee DS, Lee ES, Alam MM et al (2016) Soluble DPP-4 up-regulates toll-like receptors and augments inflammatory reactions, which are ameliorated by vildagliptin or mannose-6-phosphate. Metabolism 65:89–101
14. Makdissi A, Ghanim H, Vora M et al (2012) Sitagliptin exerts an antinflammatory action. J Clin Endocrinol Metab 97:3333–3341
15. Ta NN, Li Y, Schuyler CA, Lopes-Virella MF, Huang Y (2010) DPP-4 (CD26) inhibitor alogliptin inhibits TLR4-mediated ERK activation and ERK-dependent MMP-1 expression by U937 histiocytes. Atherosclerosis 213:429–435
16. Ervinna N, Mita T, Yasunari E et al (2013) Anagliptin, a DPP-4 inhibitor, suppresses proliferation of vascular smooth muscles and monocyte inflammatory reaction and attenuates atherosclerosis in male apo E-deficient mice. Endocrinology 154:1260–1270
17. Santaolalla R, Abreu MT (2012) Innate immunity in the small intestine. Curr Opin Gastroenterol 28:124–129
18. He YL (2012) Clinical pharmacokinetics and pharmacodynamics of vildagliptin. Clin Pharmacokinet 51:147–162
19. Delzenne NM, Neyrinck AM, Backhed F, Cani PD (2011) Targeting gut microbiota in obesity: effects of prebiotics and probiotics. Nat Rev Endocrinol 7:639–646
20. Shin NR, Lee JC, Lee HY et al (2014) An increase in the Akkermansia spp. population induced by metformin treatment improves glucose homeostasis in diet-induced obese mice. Gut 63:727–735
21. Walker ND, McEwan NR, Wallace RJ (2003) Cloning and functional expression of dipeptidyl peptidase IV from the ruminal bacterium Prevotella albensis M384(T). Microbiology 149:2227–2234
22. Stressler T, Eisele T, Schlayer M, Lutz-Wahl S, Fischer L (2013) Characterization of the recombinant exopeptidases PepX and PepN from Lactobacillus helveticus ATCC 12046 important for food protein hydrolysis. PLoS One 8:e70055
23. Sanz Y, Toldra F (2001) Purification and characterization of an X-prolyl-dipeptidyl peptidase from Lactobacillus sakei. Appl Environ Microbiol 67:1815–1820
24. Zeng Z, Luo JY, Zuo FL et al (2016) Bifidobacteria possess inhibitory activity against dipeptidyl peptidase-IV. Lett Appl Microbiol 62:250–255
25. Zhu Zeng JL, Zuo F, Chen S Screening for potential novel probiotic Lactobacillus strains based on high dipeptidyl peptidase IV and α-glucosidase inhibitory activity. J Funct Foods 20:486–495
26. Zhang Q, Xiao X, Li M et al (2017) Vildagliptin increases butyrate-producing bacteria in the gut of diabetic rats. PLoS One 12:e0184735
27. Grasset E, Puel A, Charpentier J et al (2017) A specific gut microbiota dysbiosis of type 2 diabetic mice induces GLP-1 resistance through an enteric NO-dependent and gut–brain axis mechanism. Cell Metab 25:e1075
28. Bindels LB, Neyrinck AM, Claus SP et al (2016) Synbiotic approach restores intestinal homeostasis and prolongs survival in leukaemic mice with cachexia. ISME J 10:1456–1470
29. Bindels LB, Segura Munoz RR, Gomes-Neto JC et al (2017) Resistant starch can improve insulin sensitivity independently of the gut microbiota. Microbiome 5:12
30. Salazar N, Dewulf EM, Neyrinck AM et al (2015) Inulin-type fructans modulate intestinal Bifidobacterium species populations and decrease fecal short-chain fatty acids in obese women. Clin Nutr 34:501–507
31. Neyrinck AM, Taminiau B, Walgrave H et al (2017) Spirulina protects against hepatic inflammation in aging: an effect related to the modulation of the gut microbiota? Nutrients 9
32. Neyrinck AM, Alexiou H, Delzenne NM (2004) Kupffer cell activity is involved in the hepatoprotective effect of dietary oligofructose in rats with endotoxic shock. J Nutr 134:1124–1129
33. Neyrinck AM, Gomez C, Delzenne NM (2004) Precision-cut liver slices in culture as a tool to assess the physiological involvement of Kupffer cells in hepatic metabolism. Comp Hepatol 3(Suppl 1):S45
34. Suriano F, Bindels LB, Verspreet J et al (2017) Fat binding capacity and modulation of the gut microbiota both determine the effect of wheat bran fractions on adiposity. Sci Rep 7:5621
35. Reichardt N, Duncan SH, Young P et al (2014) Phylogenetic distribution of three pathways for propionate production within the human gut microbiota. ISME J 8:1323–1335
36. Cani PD, Possemiers S, Van de Wiele T et al (2009) Changes in gut microbiota control inflammation in obese mice through a mechanism involving GLP-2-driven improvement of gut permeability. Gut 58:1091–1103
37. Richards P, Pais R, Habib AM et al (2016) High fat diet impairs the function of glucagon-like peptide-1 producing L-cells. Peptides 77:21–27
38. Psichas A, Sleeth ML, Murphy KG et al (2015) The short chain fatty acid propionate stimulates GLP-1 and PYY secretion via free fatty acid receptor 2 in rodents. Int J Obes 39:424–429
39. Vaishnava S, Behrendt CL, Ismail AS, Eckmann L, Hooper LV (2008) Paneth cells directly sense gut commensals and maintain homeostasis at the intestinal host–microbial interface. Proc Natl Acad Sci U S A 105:20858–20863
40. De A, Pompilio A, Francis J et al (2018) Antidiabetic drugs ‘gliptins’ affect biofilm formation by Streptococcus mutans. Microbiol Res 209:79–85
41. Lam YY, Ha CW, Campbell CR et al (2012) Increased gut permeability and microbiota change associate with mesenteric fat inflammation and metabolic dysfunction in diet-induced obese mice. PLoS One 7:e34233
42. Moya-Perez A, Neef A, Sanz Y (2015) Bifidobacterium pseudocatenulatum CECT 7765 reduces obesity-associated inflammation by restoring the lymphocyte–macrophage balance and gut microbiota structure in high-fat diet-fed mice. PLoS One 10:e0126976
43. Geurts L, Lazarevic V, Derrien M et al (2011) Altered gut microbiota and endocannabinoid system tone in obese and diabetic leptin-resistant mice: impact on apelin regulation in adipose tissue. Front Microbiol 2:149
44. Scaldaferri F, Pizzoferrato M, Gerardi V, Lopetuso L, Gasbarrini A (2012) The gut barrier: new acquisitions and therapeutic approaches. J Clin Gastroenterol 46(Suppl):S12–S17
45. Everard A, Lazarevic V, Gaia N et al (2014) Microbiome of prebiotic-treated mice reveals novel targets involved in host response during obesity. ISME J 8:2116–2130
46. Lee SJ, Lee J, Li KK et al (2012) Disruption of the murine Glp2r impairs Paneth cell function and increases susceptibility to small bowel enteritis. Endocrinology 153:1141–1151
47. Drucker DJ, Erlich P, Asa SL, Brubaker PL (1996) Induction of intestinal epithelial proliferation by glucagon-like peptide 2. Proc Natl Acad Sci U S A 93:7911–7916
48. Briand F, Brousseau E, Quinsat M, Burcelin R, Sulpice T (2018) Obeticholic acid raises LDL-cholesterol and reduces HDL-cholesterol in the diet-induced NASH (DIN) hamster model. Eur J Pharmacol 818:449–456
49. Sheng L, Jena PK, Hu Y et al (2017) Hepatic inflammation caused by dysregulated bile acid synthesis is reversible by butyrate supplementation. J Pathol 243:431–441
50. Scheen AJ (2010) Pharmacokinetics of dipeptidylpeptidase-4 inhibitors. Diabetes Obes Metab 12:648–658